Korean Journal of Radiology

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Significance of Volume-Based PET Parameters in Cancer Patients

  • Moon, Seung Hwan (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Hyun, Seung Hyup (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Choi, Joon Young (Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Published : 2013.02.01
⟨ Previous Next ⟩

Abstract

Accurate prediction of cancer prognosis before the start of treatment is important since these predictions often affect the choice of treatment. Prognosis is usually based on anatomical staging and other clinical factors. However, the conventional system is not sufficient to accurately and reliably determine prognosis. Metabolic parameters measured by $^{18}F$-fluorodeoxyglucose (FDG) positron emission tomography (PET) have the potential to provide valuable information regarding prognosis and treatment response evaluation in cancer patients. Among these parameters, volume-based PET parameters such as metabolic tumor volume and total lesion glycolysis are especially promising. However, the measurement of these parameters is significantly affected by the imaging methodology and specific image characteristics, and a standard method for these parameters has not been established. This review introduces volume-based PET parameters as potential prognostic indicators, and highlights methodological considerations for measurement, potential implications, and prospects for further studies.

Keywords

References

  1. Takes, RP, Rinaldo, A, Silver, CE, Piccirillo, JF, Haigentz, M, Suárez, C,Future of the TNM classification and staging system in head and neck cancer, Head Neck, 32, 1, 1693-1711(2010) https://doi.org/10.1002/hed.21361
  2. Lee, P, Weerasuriya, DK, Lavori, PW, Quon, A, Hara, W, Maxim, PG,Metabolic tumor burden predicts for disease progression and death in lung cancer, Int J Radiat Oncol Biol Phys, 69, 2, 328-333(2007) https://doi.org/10.1016/j.ijrobp.2007.04.036
  3. Mirsadraee, S, Oswal, D, Alizadeh, Y, Caulo, A, van Beek, E,The 7th lung cancer TNM classification and staging system: Review of the changes and implications, World J Radiol, 4, 3, 128-134(2012)
  4. Walters, TK, Zuckerman, J, Nisbet-Smith, A, Hudson, E, Chia, Y, Burke, M,Fine needle aspiration biopsy in the diagnosis and management of fibroadenoma of the breast, Br J Surg, 77, 4, 1215-1217(1990) https://doi.org/10.1002/bjs.1800771107
  5. Chun, YH, Kim, SU, Park, JY, Y Kim, do, Han, KH, Chon, CY,Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma, Eur J Cancer, 47, 5, 2568-2575(2011) https://doi.org/10.1016/j.ejca.2011.07.002
  6. Soret, M, Bacharach, SL, Buvat, I,Partial-volume effect in PET tumor imaging, J Nucl Med, 48, 6, 932-945(2007) https://doi.org/10.2967/jnumed.106.035774
  7. Vanderhoek, M, Perlman, SB, Jeraj, R,Impact of the definition of peak standardized uptake value on quantification of treatment response, J Nucl Med, 53, 7, 4-11(2012) https://doi.org/10.2967/jnumed.111.093443
  8. Larson, SM, Erdi, Y, Akhurst, T, Mazumdar, M, Macapinlac, HA, Finn, RD,Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis, Clin Positron Imaging, 2, 8, 159-171(1999) https://doi.org/10.1016/S1095-0397(99)00016-3
  9. Moon, SH, Choi, JY, Lee, HJ, Son, YI, Baek, CH, Ahn, YC,Prognostic value of F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: Comparisons of volume-based metabolic parameters, Head Neck, , 9, (2012)
  10. Geets, X, Lee, JA, Bol, A, Lonneux, M, Gregoire, V,A gradient-based method for segmenting FDG-PET images: methodology and validation, Eur J Nucl Med Mol Imaging, 34, 10, 1427-1438(2007) https://doi.org/10.1007/s00259-006-0363-4
  11. Schaefer, A, Kremp, S, Hellwig, D, Rube, C, Kirsch, CM, Nestle, U,A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data, Eur J Nucl Med Mol Imaging, 35, 11, 1989-1999(2008) https://doi.org/10.1007/s00259-008-0875-1
  12. van Dalen, JA, Hoffmann, AL, Dicken, V, Vogel, WV, Wiering, B, Ruers, TJ,A novel iterative method for lesion delineation and volumetric quantification with FDG PET, Nucl Med Commun, 28, 12, 485-493(2007) https://doi.org/10.1097/MNM.0b013e328155d154
  13. Boellaard, R, Krak, NC, Hoekstra, OS, Lammertsma, AA,Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study, J Nucl Med, 45, 13, 1519-1527(2004)
  14. Paulino, AC, Koshy, M, Howell, R, Schuster, D, Davis, LW,Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer, Int J Radiat Oncol Biol Phys, 61, 14, 1385-1392(2005) https://doi.org/10.1016/j.ijrobp.2004.08.037
  15. MacManus, M, Nestle, U, Rosenzweig, KE, Carrio, I, Messa, C, Belohlavek, O,Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007, Radiother Oncol, 91, 15, 85-94(2009) https://doi.org/10.1016/j.radonc.2008.11.008
  16. Zhong, X, Yu, J, Zhang, B, Mu, D, Zhang, W, Li, D,Using F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus, Int J Radiat Oncol Biol Phys, 73, 16, 136-141(2009) https://doi.org/10.1016/j.ijrobp.2008.04.015
  17. Hyun, SH, Choi, JY, Shim, YM, Kim, K, Lee, SJ, Cho, YS,Prognostic value of metabolic tumor volume measured by F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma, Ann Surg Oncol, 17, 17, 115-122(2010) https://doi.org/10.1245/s10434-009-0719-7
  18. Cheebsumon, P, Yaqub, M, van Velden, FH, Hoekstra, OS, Lammertsma, AA, Boellaard, R,Impact of [F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology, Eur J Nucl Med Mol Imaging, 38, 18, 2136-2144(2011) https://doi.org/10.1007/s00259-011-1899-5
  19. Meng, X, Sun, X, Mu, D, Xing, L, Ma, L, Zhang, B,Noninvasive evaluation of microscopic tumor extensions using standardized uptake value and metabolic tumor volume in non-small-cell lung cancer, Int J Radiat Oncol Biol Phys, 82, 19, 960-966(2012) https://doi.org/10.1016/j.ijrobp.2010.10.064
  20. Juweid, ME, Stroobants, S, Hoekstra, OS, Mottaghy, FM, Dietlein, M, Guermazi, A,Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma, J Clin Oncol, 25, 20, 571-578(2007) https://doi.org/10.1200/JCO.2006.08.2305
  21. Le Roux, PY, Gastinne, T, Le Gouill, S, Nowak, E, Bodet-Milin, C, Querellou, S,Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria, Eur J Nucl Med Mol Imaging, 38, 21, 1064-1071(2011) https://doi.org/10.1007/s00259-011-1741-0
  22. de Jong, PA, van Ufford, HM, Baarslag, HJ, de Haas, MJ, Wittebol, SH, Quekel, LG,CT and F-FDG PET for noninvasive detection of splenic involvement in patients with malignant lymphoma, AJR Am J Roentgenol, 192, 22, 745-753(2009) https://doi.org/10.2214/AJR.08.1160
  23. Hatt, M, Visvikis, D, Albarghach, NM, Tixier, F, Pradier, O, Cheze-le Rest, C,Prognostic value of F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology, Eur J Nucl Med Mol Imaging, 38, 23, 1191-1202(2011) https://doi.org/10.1007/s00259-011-1755-7
  24. Cheebsumon, P, van Velden, FH, Yaqub, M, Frings, V, de Langen, AJ, Hoekstra, OS,Effects of image characteristics on performance of tumor delineation methods: a test-retest assessment, J Nucl Med, 52, 24, 1550-1558(2011) https://doi.org/10.2967/jnumed.111.088914
  25. Kim, K, Kim, SJ, Kim, IJ, Kim, YS, Pak, K, Kim, H,Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer, Nucl Med Commun, 33, 25, 613-620(2012) https://doi.org/10.1097/MNM.0b013e328351d4f5
  26. Daisne, JF, Sibomana, M, Bol, A, Doumont, T, Lonneux, M, Grégoire, V,Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms, Radiother Oncol, 69, 26, 247-250(2003) https://doi.org/10.1016/S0167-8140(03)00270-6
  27. Hatt, M, Le Pogam, A, Visvikis, D, Pradier, O, Cheze Le Rest, C,Impact of partial-volume effect correction on the predictive and prognostic value of baseline F-FDG PET images in esophageal cancer, J Nucl Med, 53, 27, 12-20(2012) https://doi.org/10.2967/jnumed.111.092775
  28. Nehmeh, SA, Erdi, YE, Ling, CC, Rosenzweig, KE, Schoder, H, Larson, SM,Effect of respiratory gating on quantifying PET images of lung cancer, J Nucl Med, 43, 28, 876-881(2002)
  29. Cheebsumon, P, van Velden, FH, Yaqub, M, Hoekstra, CJ, Velasquez, LM, Hayes, W,Measurement of metabolic tumor volume: static versus dynamic FDG scans, EJNMMI Res, 1, 29, 35(2011) https://doi.org/10.1186/2191-219X-1-35
  30. Arslan, N, Tuncel, M, Kuzhan, O, Alagoz, E, Budakoglu, B, Ozet, A,Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-F fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer, Ann Nucl Med, 25, 30, 406-413(2011) https://doi.org/10.1007/s12149-011-0478-y
  31. Liao, S, Penney, BC, Wroblewski, K, Zhang, H, Simon, CA, Kampalath, R,Prognostic value of metabolic tumor burden on F-FDG PET in nonsurgical patients with non-small cell lung cancer, Eur J Nucl Med Mol Imaging, 39, 31, 27-38(2012) https://doi.org/10.1007/s00259-011-1934-6
  32. Chan, SC, Chang, JT, Lin, CY, Ng, SH, Wang, HM, Liao, CT,Clinical utility of F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification, Nucl Med Commun, 32, 32, 989-996(2011) https://doi.org/10.1097/MNM.0b013e3283495662
  33. Chu, KP, Murphy, JD, La, TH, Krakow, TE, Iagaru, A, Graves, EE,Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes, Int J Radiat Oncol Biol Phys, 83, 33, 1521-1527(2012) https://doi.org/10.1016/j.ijrobp.2011.10.022
  34. La, TH, Filion, EJ, Turnbull, BB, Chu, JN, Lee, P, Nguyen, K,Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer, Int J Radiat Oncol Biol Phys, 74, 34, 1335-1341(2009) https://doi.org/10.1016/j.ijrobp.2008.10.060
  35. Xie, P, Yue, JB, Zhao, HX, Sun, XD, Kong, L, Fu, Z,Prognostic value of F-FDG PET-CT metabolic index for nasopharyngeal carcinoma, J Cancer Res Clin Oncol, 136, 35, 883-889(2010) https://doi.org/10.1007/s00432-009-0729-7
  36. Choi, KH, Yoo, IR, Han, EJ, Kim, YS,Prognostic Value of Metabolic Tumor Volume Measured by F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated by Surgery, Nucl Med Mol Imaging, 45, 36, 43-51(2011) https://doi.org/10.1007/s13139-010-0063-7
  37. Guillem, JG, Moore, HG, Akhurst, T, Klimstra, DS, Ruo, L, Mazumdar, M,Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer, J Am Coll Surg, 199, 37, 1-7(2004)
  38. Gulec, SA, Suthar, RR, Barot, TC, Pennington, K,The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing Y selective internal radiation therapy plus chemotherapy, Eur J Nucl Med Mol Imaging, 38, 38, 1289-1295(2011) https://doi.org/10.1007/s00259-011-1758-4
  39. Chung, HH, Kwon, HW, Kang, KW, Park, NH, Song, YS, Chung, JK,Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer, Ann Surg Oncol, 19, 39, 1966-1972(2012) https://doi.org/10.1245/s10434-011-2153-x
  40. Kim, BS, Kim, IJ, Kim, SJ, Nam, NH, Park, KJ, Kim, K,The Prognostic value of the metabolic tumor volume in FIGO stage IA to IIB cervical cancer for tumor recurrence: measured by F-18 FDG PET/CT, Nucl Med Mol Imaging, 45, 40, 36-42(2011) https://doi.org/10.1007/s13139-010-0062-8
  41. Schaefer, NG, Veit-Haibach, P, Soyka, JD, Steinert, HC, Stahel, RA,Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of F-FDG-PET/CT, Eur J Radiol, 81, 41, e19-e25(2012) https://doi.org/10.1016/j.ejrad.2010.11.006
  42. Costelloe, CM, Macapinlac, HA, Madewell, JE, Fitzgerald, NE, Mawlawi, OR, Rohren, EM,F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma, J Nucl Med, 50, 42, 340-347(2009) https://doi.org/10.2967/jnumed.108.058461
  43. Yoo, J, Choi, JY, Lee, KT, Heo, JS, Park, SB, Moon, SH,Prognostic significance of volume-based metabolic parameters by F-FDG PET/CT in gallbladder carcinoma, Nucl Med Mol Imaging, 46, 43, 201-206(2012) https://doi.org/10.1007/s13139-012-0147-7
  44. Lee, HY, Hyun, SH, Lee, KS, Kim, BT, Kim, J, Shim, YM,Volume-based parameter of F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications, Ann Surg Oncol, 17, 44, 2787-2794(2010) https://doi.org/10.1245/s10434-010-1107-z
  45. Kang, H, Lee, HY, Lee, KS, Kim, JH,Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts, Korean J Radiol, 13, 45, 371-390(2012) https://doi.org/10.3348/kjr.2012.13.4.371
  46. Kiyohara, S, Nagamachi, S, Wakamatsu, H, Nishii, R, Fujita, S, Futami, S,[Usefulness of metabolic volume and total lesion glycolysis for predicting therapeutic response in cancer therapy by F-FDG PET/CT], Kaku Igaku, 47, 46, 453-461(2010)
  47. Brepoels, L, De Saint-Hubert, M, Stroobants, S, Verhoef, G, Balzarini, J, Mortelmans, L,Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [F]FDG PET, Eur J Nucl Med Mol Imaging, 37, 47, 1688-1695(2010) https://doi.org/10.1007/s00259-010-1479-0
  48. Melton, GB, Lavely, WC, Jacene, HA, Schulick, RD, Choti, MA, Wahl, RL,Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy, J Gastrointest Surg, 11, 48, 961-969(2007) https://doi.org/10.1007/s11605-007-0170-7
  49. Im, HJ, Kim, TS, Park, SY, Min, HS, Kim, JH, Kang, HG,Prediction of tumour necrosis fractions using metabolic and volumetric F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma, Eur J Nucl Med Mol Imaging, 39, 49, 39-49(2012) https://doi.org/10.1007/s00259-011-1936-4
  50. Roedl, JB, Colen, RR, Holalkere, NS, Fischman, AJ, Choi, NC, Blake, MA,Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation, Radiother Oncol, 89, 50, 278-286(2008) https://doi.org/10.1016/j.radonc.2008.06.014
  51. Arslan, N, Miller, TR, Dehdashti, F, Battafarano, RJ, Siegel, BA,Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer, Mol Imaging Biol, 4, 51, 301-310(2002) https://doi.org/10.1016/S1536-1632(02)00011-2
  52. Ruby, JA, Leibold, T, Akhurst, TJ, Shia, J, Saltz, LB, Mazumdar, M,FDG-PET assessment of rectal cancer response to neoadjuvant chemoradiotherapy is not associated with long-term prognosis: a prospective evaluation, Dis Colon Rectum, 55, 52, 378-386(2012) https://doi.org/10.1097/DCR.0b013e318244a666
  53. Edet-Sanson, A, Dubray, B, Doyeux, K, Back, A, Hapdey, S, Modzelewski, R,Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC), Radiother Oncol, 102, 53, 251-257(2012) https://doi.org/10.1016/j.radonc.2011.07.023
  54. Akhurst, T, Ng, V, Larson, SM, O'Donoghue, JA, O'Neel, J, Erdi, Y,Tumor Burden Assessment with Positron Emission Tomography with, Clin Positron Imaging, 3, 54, 57-65(2000) https://doi.org/10.1016/S1095-0397(00)00041-8
  55. M O'BRIEN, Robert,A caution regarding rules of thumb for variance inflation factors, Qual Quant, 41, 55, 673-690(2007) https://doi.org/10.1007/s11135-006-9018-6
  56. Chan, WK, Mak, HK, Huang, B, Yeung, DW, Kwong, DL, Khong, PL,Nasopharyngeal carcinoma: relationship between F-FDG PET-CT maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis and TNM classification, Nucl Med Commun, 31, 56, 206-210(2010) https://doi.org/10.1097/MNM.0b013e328333e3ef
  57. Chang, KP, Tsang, NM, Liao, CT, Hsu, CL, Chung, MJ, Lo, CW,Prognostic significance of F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma, J Nucl Med, 53, 57, 21-28(2012) https://doi.org/10.2967/jnumed.111.090696
  58. Gu, J, Khong, PL, Wang, S, Chan, Q, Law, W, Zhang, J,Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT, Mol Imaging Biol, 13, 58, 1020-1028(2011) https://doi.org/10.1007/s11307-010-0433-7
  59. Jansen, JF, Schöder, H, Lee, NY, Stambuk, HE, Wang, Y, Fury, MG,Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [F]FDG-PET, Int J Radiat Oncol Biol Phys, 82, 59, 299-307(2012) https://doi.org/10.1016/j.ijrobp.2010.11.022
  60. Aboagye, EO, Bhujwalla, ZM,Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells, Cancer Res, 59, 60, 80-84(1999)
  61. Oh, JR, Seo, JH, Chong, A, Min, JJ, Song, HC, Kim, YC,Whole-body metabolic tumour volume of F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer, Eur J Nucl Med Mol Imaging, 39, 61, 925-935(2012) https://doi.org/10.1007/s00259-011-2059-7
  62. Zhu, D, Ma, T, Niu, Z, Zheng, J, Han, A, Zhao, S,Prognostic significance of metabolic parameters measured by F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer, Lung Cancer, 73, 62, 332-337(2011) https://doi.org/10.1016/j.lungcan.2011.01.007

Cited by

  1. Prognostic value of metabolic tumor volume as measured by fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in nasopharyngeal carcinoma : Prognostic value of MTV by PET/C vol.4, pp.10, 2013, https://doi.org/10.1002/alr.21363
  2. Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma vol.41, pp.4, 2014, https://doi.org/10.1007/s00259-013-2618-1
  3. Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology vol.48, pp.1, 2013, https://doi.org/10.1007/s13139-013-0260-2
  4. Tumor SUVmax Normalized to Liver Uptake on 18F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer vol.48, pp.4, 2014, https://doi.org/10.1007/s13139-014-0289-x
  5. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-Analysis vol.55, pp.6, 2013, https://doi.org/10.2967/jnumed.113.133801
  6. Positron Emission Tomography/Magnetic Resonance Imaging Evaluation of Lung Cancer: Current Status and Future Prospects vol.29, pp.1, 2013, https://doi.org/10.1097/rti.0000000000000062
  7. Prognostic Significance of Volume-Based FDG PET/CT Parameters in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation Therapy vol.55, pp.6, 2014, https://doi.org/10.3349/ymj.2014.55.6.1498
  8. FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity vol.205, pp.2, 2013, https://doi.org/10.2214/ajr.14.13830
  9. Volume-Based Assessment With18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer vol.205, pp.3, 2015, https://doi.org/10.2214/ajr.14.13847
  10. State-Of-The-Art and Recent Advances in Quantification for Therapeutic Follow-Up in Oncology Using PET vol.2, pp.None, 2013, https://doi.org/10.3389/fmed.2015.00018
  11. Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy vol.120, pp.4, 2015, https://doi.org/10.1007/s11547-014-0446-4
  12. The significance of pretreatment SUV (max) in the algorithm of “chemoradioselection” strategy for hypopharyngeal squamous cell carcinoma: a single-center experience vol.41, pp.1, 2015, https://doi.org/10.5981/jjhnc.41.63
  13. Comparison of 18F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer vol.40, pp.5, 2013, https://doi.org/10.1007/s00261-014-0277-8
  14. Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy vol.8, pp.2, 2013, https://doi.org/10.3342/ceo.2015.8.2.142
  15. Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma vol.10, pp.10, 2013, https://doi.org/10.1371/journal.pone.0140830
  16. The prognostic value of baseline 18F-FDG PET/CT in steroid-naïve large-vessel vasculitis: introduction of volume-based parameters vol.43, pp.2, 2016, https://doi.org/10.1007/s00259-015-3148-9
  17. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma vol.30, pp.4, 2016, https://doi.org/10.1007/s12149-016-1059-x
  18. Functional volumetric analysis of striatum using F-18 FP-CIT PET in patients with idiopathic Parkinson’s disease and normal subjects vol.30, pp.8, 2016, https://doi.org/10.1007/s12149-016-1096-5
  19. Total Lesion Glycolysis Using 18 F-FDG PET/CT as a Prognostic Factor for Locally Advanced Esophageal Cancer vol.31, pp.1, 2013, https://doi.org/10.3346/jkms.2016.31.1.39
  20. Prognostic significance of volume-based 18F-FDG PET/CT parameter in patients with surgically resected non-small cell lung cancer : Comparison with immunohistochemical biomarkers vol.55, pp.1, 2016, https://doi.org/10.3413/nukmed-0754-15-07
  21. 18 F-fluorodeoxyglucose positron emission tomography/computed tomography comparison of gastric lymphoma and gastric carcinoma vol.22, pp.34, 2013, https://doi.org/10.3748/wjg.v22.i34.7787
  22. Prognostic Value of 18 F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis vol.11, pp.1, 2016, https://doi.org/10.1371/journal.pone.0146195
  23. The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer vol.95, pp.5, 2016, https://doi.org/10.1097/md.0000000000002772
  24. Total 18F-FDG PET/CT Metabolic Tumor Volume Is Associated With Postoperative Biochemical Response in Patients With Metastatic Pheochromocytomas and Paragangliomas vol.263, pp.3, 2013, https://doi.org/10.1097/sla.0000000000001018
  25. Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual‐phase 18FDG PET‐CT imaging in patients with head and neck cancer vol.38, pp.suppl1, 2013, https://doi.org/10.1002/hed.24048
  26. Prognostic significance of clinical and 18F‐FDG PET/CT parameters for post‐distant metastasis survival in head and neck squamous cell carcinoma patients vol.114, pp.7, 2013, https://doi.org/10.1002/jso.24412
  27. Verification of the tumor volume delineation method using a fixed threshold of peak standardized uptake value vol.10, pp.3, 2013, https://doi.org/10.1007/s12194-017-0405-6
  28. Risk of Malignancy in Thyroid Incidentaloma is Not Increased in Overweight or Obese Patients, but in Young Patients vol.69, pp.4, 2017, https://doi.org/10.1080/01635581.2017.1299877
  29. Prognostic value of 18 F-FDG-PET/CT parameters in patients with pancreatic carcinoma : A systematic review and meta-analysis vol.96, pp.33, 2017, https://doi.org/10.1097/md.0000000000007813
  30. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma vol.9, pp.373, 2013, https://doi.org/10.1126/scitranslmed.aag2196
  31. Clinically determined type of 18 F-fluoro-2-deoxyglucose uptake as an alternative prognostic marker in resectable pancreatic cancer vol.12, pp.2, 2013, https://doi.org/10.1371/journal.pone.0172606
  32. Prognostic value of pretreatment 18 F-FDG PET-CT for nasopharyngeal carcinoma patients vol.96, pp.17, 2013, https://doi.org/10.1097/md.0000000000006721
  33. Prognostic value of metabolic parameters determined by preoperative 18 F-FDG PET/CT in patients with uterine carcinosarcoma vol.28, pp.4, 2013, https://doi.org/10.3802/jgo.2017.28.e43
  34. The clinical utility of splenic fluorodeoxyglucose uptake for diagnosis and prognosis in patients with macrophage activation syndrome vol.96, pp.34, 2017, https://doi.org/10.1097/md.0000000000007901
  35. Prognostic Value of Percentage Change in Metabolic Parameters as Measured by Dual-Time Point 18 F-FDG PET/CT in Premenopausal Women with Invasive Ductal Breast Carcinoma vol.26, pp.10, 2017, https://doi.org/10.1089/jwh.2016.6256
  36. Comparison of novel multi-level Otsu (MO-PET) and conventional PET segmentation methods for measuring FDG metabolic tumor volume in patients with soft tissue sarcoma vol.4, pp.1, 2013, https://doi.org/10.1186/s40658-017-0189-0
  37. Analysis of Prognostic Values of Various PET Metrics in Preoperative 18F-FDG PET for Early-Stage Bronchial Carcinoma for Progression-Free and Overall Survival: Significantly Increased Glyco vol.58, pp.12, 2013, https://doi.org/10.2967/jnumed.117.189894
  38. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status vol.21, pp.2, 2018, https://doi.org/10.1007/s10120-017-0739-0
  39. Meta-analysis of meta-analyses in oncologic positron emission tomography vol.39, pp.12, 2013, https://doi.org/10.1097/mnm.0000000000000908
  40. Prognostic value of metabolic tumor volume of pretreatment 18 F-FAMT PET/CT in non-small cell lung Cancer vol.18, pp.None, 2018, https://doi.org/10.1186/s12880-018-0292-2
  41. Prognostic Value of Volume-Based Metabolic Parameters of 18F-FDG PET/CT in Uterine Cervical Cancer: A Systematic Review and Meta-Analysis vol.211, pp.5, 2013, https://doi.org/10.2214/ajr.18.19734
  42. Quantitative 18 F-FDG PET analysis in survival rate prediction of patients with non-small cell lung cancer vol.16, pp.4, 2013, https://doi.org/10.3892/ol.2018.9166
  43. Natural Postoperative Bone Metabolic Changes after Total Knee Arthroplasty Determined by Positron Emission Tomography Scans vol.8, pp.12, 2018, https://doi.org/10.4236/ojo.2018.812046
  44. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non–Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy vol.43, pp.1, 2013, https://doi.org/10.1097/rlu.0000000000001886
  45. Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? vol.52, pp.1, 2018, https://doi.org/10.1007/s13139-017-0493-6
  46. Prognostic value of the maximum standardized uptake value of pre-treatment primary lesions in small-cell lung cancer on 18F-FDG PET/CT: a meta-analysis vol.59, pp.9, 2018, https://doi.org/10.1177/0284185117745907
  47. Tumor volume delineation: A pilot study comparing a digital positron-emission tomography prototype with an analog positron-emission tomography system vol.18, pp.1, 2019, https://doi.org/10.4103/wjnm.wjnm_22_18
  48. Prediction of Overall Survival and Progression-Free Survival by the 18F-FDG PET/CT Radiomic Features in Patients with Primary Gastric Diffuse Large B-Cell Lymphoma vol.2019, pp.None, 2013, https://doi.org/10.1155/2019/5963607
  49. Radiomics in Oncological PET/CT: a Methodological Overview vol.53, pp.1, 2013, https://doi.org/10.1007/s13139-019-00571-4
  50. Metabolic tumor burden on postsurgical PET/CT predicts survival of patients with gastric cancer vol.19, pp.None, 2013, https://doi.org/10.1186/s40644-019-0205-9
  51. Prognostic Value of Metabolic Information in Advanced Gastric Cancer Using Preoperative 18F-FDG PET/CT vol.53, pp.6, 2013, https://doi.org/10.1007/s13139-019-00622-w
  52. Correlations between the metabolic profile and 18F-FDG-Positron Emission Tomography-Computed Tomography parameters reveal the complexity of the metabolic reprogramming within lung cancer patients vol.9, pp.1, 2013, https://doi.org/10.1038/s41598-019-52667-8
  53. Volumetric parameters on 18F-FDG PET/CT predict the survival of patients with gastric cancer associated with their expression status of c-MET vol.19, pp.1, 2013, https://doi.org/10.1186/s12885-019-5935-3
  54. Multiparametric quantitative and texture 18 F-FDG PET/CT analysis for primary malignant tumour grade differentiation vol.3, pp.1, 2013, https://doi.org/10.1186/s41747-019-0124-3
  55. Predicting tumor recurrence using metabolic indices of 18 F-FDG PET/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma vol.20, pp.2, 2020, https://doi.org/10.3892/ol.2020.11681
  56. Prognostic value of [18F]FDG PET/CT parameters in surgically resected primary lung adenocarcinoma: a single-center experience vol.106, pp.3, 2013, https://doi.org/10.1177/0300891620904404
  57. 18F-FDG PET/CT imaging of vulva cancer recurrence: A comparison of PET-derived metabolic parameters between women with and without HIV infection vol.59, pp.6, 2013, https://doi.org/10.1055/a-1221-7810
  58. Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Surgically Treated Stage I Lung Adenocarcinoma Patients vol.46, pp.8, 2013, https://doi.org/10.1097/rlu.0000000000003714
  59. PET/MRI in Cervical Cancer: Associations Between Imaging Biomarkers and Tumor Stage, Disease Progression, and Overall Survival vol.53, pp.1, 2013, https://doi.org/10.1002/jmri.27311
  60. Prognostic Value of MTV and TLG of 18F-FDG PET in Patients with Stage I and II Non-Small-Cell Lung Cancer: a Meta-Analysis vol.2021, pp.None, 2021, https://doi.org/10.1155/2021/7528971
  61. Predictive Value of Metabolic Parameters Derived From 18F-FDG PET/CT for Microsatellite Instability in Patients With Colorectal Carcinoma vol.12, pp.None, 2013, https://doi.org/10.3389/fimmu.2021.724464
  62. Prognostic Significance of Metabolic Parameters by 18F-FDG PET/CT in Thymic Epithelial Tumors vol.13, pp.4, 2021, https://doi.org/10.3390/cancers13040712
  63. Estimating the Potential of Radiomics Features and Radiomics Signature from Pretherapeutic PSMA-PET-CT Scans and Clinical Data for Prediction of Overall Survival When Treated with 177Lu-PSMA vol.11, pp.2, 2013, https://doi.org/10.3390/diagnostics11020186
  64. Defining the Optimal Method for Measuring Metabolic Tumor Volume on Preoperative 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography as a Prognostic Predictor in Patients With Panc vol.11, pp.None, 2013, https://doi.org/10.3389/fonc.2021.646141
  65. Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by 18F-FDG PET/CT Radiomics and Clinicopathological Characteristics vol.11, pp.None, 2013, https://doi.org/10.3389/fonc.2021.789014
  66. Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer and Its Relationship with Demographic-Histopathologic Risk Factors and 18 F-Fluorodeoxyglucose Positron Emission Tomogr vol.36, pp.5, 2013, https://doi.org/10.1089/cbr.2019.3203
  67. Analysis of PET parameters as prognosticators of survival and tumor extent in Oropharyngeal Cancer treated with surgery and postoperative radiotherapy vol.21, pp.1, 2013, https://doi.org/10.1186/s12885-021-08035-9
  68. Prognostic Value of Pretherapeutic Primary Tumor MTV from [18F]FDG PET in Radically Treated Cervical Cancer Patients vol.11, pp.12, 2021, https://doi.org/10.3390/metabo11120809